221 related articles for article (PubMed ID: 10753182)
1. Threshold mechanisms and site specificity in chromium(VI) carcinogenesis.
De Flora S
Carcinogenesis; 2000 Apr; 21(4):533-41. PubMed ID: 10753182
[TBL] [Abstract][Full Text] [Related]
2. Estimates of the chromium(VI) reducing capacity in human body compartments as a mechanism for attenuating its potential toxicity and carcinogenicity.
De Flora S; Camoirano A; Bagnasco M; Bennicelli C; Corbett GE; Kerger BD
Carcinogenesis; 1997 Mar; 18(3):531-7. PubMed ID: 9067553
[TBL] [Abstract][Full Text] [Related]
3. Metabolic reduction of chromium, as related to its carcinogenic properties.
De Flora S; Serra D; Camoirano A; Zanacchi P
Biol Trace Elem Res; 1989; 21():179-87. PubMed ID: 2484584
[TBL] [Abstract][Full Text] [Related]
4. Lack of genotoxic effects in hematopoietic and gastrointestinal cells of mice receiving chromium(VI) with the drinking water.
De Flora S; D'Agostini F; Balansky R; Micale R; Baluce B; Izzotti A
Mutat Res; 2008; 659(1-2):60-7. PubMed ID: 18155955
[TBL] [Abstract][Full Text] [Related]
5. Oral chromium(VI) does not affect the frequency of micronuclei in hematopoietic cells of adult mice and of transplacentally exposed fetuses.
De Flora S; Iltcheva M; Balansky RM
Mutat Res; 2006 Nov; 610(1-2):38-47. PubMed ID: 16872865
[TBL] [Abstract][Full Text] [Related]
6. Human health risk and exposure assessment of chromium (VI) in tap water.
Paustenbach DJ; Finley BL; Mowat FS; Kerger BD
J Toxicol Environ Health A; 2003 Jul; 66(14):1295-339. PubMed ID: 12851114
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic insights from the NTP studies of chromium.
Witt KL; Stout MD; Herbert RA; Travlos GS; Kissling GE; Collins BJ; Hooth MJ
Toxicol Pathol; 2013 Feb; 41(2):326-42. PubMed ID: 23334696
[TBL] [Abstract][Full Text] [Related]
8. Metabolic reduction of chromium as a threshold mechanism limiting its in vivo activity.
Petrilli FL; de Flora S
Sci Total Environ; 1988 Jun; 71(3):357-64. PubMed ID: 3043658
[TBL] [Abstract][Full Text] [Related]
9. Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium.
Kirman CR; Hays SM; Aylward LL; Suh M; Harris MA; Thompson CM; Haws LC; Proctor DM
Chem Biol Interact; 2012 Oct; 200(1):45-64. PubMed ID: 22981460
[TBL] [Abstract][Full Text] [Related]
10. Is hexavalent chromium carcinogenic via ingestion? A weight-of-evidence review.
Proctor DM; Otani JM; Finley BL; Paustenbach DJ; Bland JA; Speizer N; Sargent EV
J Toxicol Environ Health A; 2002 May; 65(10):701-46. PubMed ID: 12028825
[TBL] [Abstract][Full Text] [Related]
11. Consideration of non-linear, non-threshold and threshold approaches for assessing the carcinogenicity of oral exposure to hexavalent chromium.
Haney J
Regul Toxicol Pharmacol; 2015 Dec; 73(3):834-52. PubMed ID: 26493004
[TBL] [Abstract][Full Text] [Related]
12. Hexavalent chrome: threshold concept for carcinogenicity.
Jones RE
Biomed Environ Sci; 1990 Mar; 3(1):20-34. PubMed ID: 2184841
[TBL] [Abstract][Full Text] [Related]
13. Chemical-specific health consultation for chromated copper arsenate chemical mixture: port of Djibouti.
Chou S; Colman J; Tylenda C; De Rosa C
Toxicol Ind Health; 2007 May; 23(4):183-208. PubMed ID: 18429380
[TBL] [Abstract][Full Text] [Related]
14. Molecular and cellular mechanisms of hexavalent chromium-induced lung cancer: an updated perspective.
Urbano AM; Ferreira LM; Alpoim MC
Curr Drug Metab; 2012 Mar; 13(3):284-305. PubMed ID: 22455553
[TBL] [Abstract][Full Text] [Related]
15. Toxicology and carcinogenesis studies of sodium dichromate dihydrate (Cas No. 7789-12-0) in F344/N rats and B6C3F1 mice (drinking water studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2008 Jul; (546):1-192. PubMed ID: 18716633
[TBL] [Abstract][Full Text] [Related]
16. Chromium carcinogenicity: California strategies.
Alexeeff GV; Satin K; Painter P; Zeise L; Popejoy C; Murchison G
Sci Total Environ; 1989 Oct; 86(1-2):159-68. PubMed ID: 2602933
[TBL] [Abstract][Full Text] [Related]
17. Induction of apoptosis in the lung but not in the liver of rats receiving intra-tracheal instillations of chromium(VI).
D'Agostini F; Izzotti A; Bennicelli C; Camoirano A; Tampa E; De Flora S
Carcinogenesis; 2002 Apr; 23(4):587-93. PubMed ID: 11960910
[TBL] [Abstract][Full Text] [Related]
18. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium.
Thompson CM; Bichteler A; Rager JE; Suh M; Proctor DM; Haws LC; Harris MA
Mutat Res Genet Toxicol Environ Mutagen; 2016 Apr; 800-801():28-34. PubMed ID: 27085472
[TBL] [Abstract][Full Text] [Related]
19. A physiologically based model for the ingestion of chromium(III) and chromium(VI) by humans.
O'Flaherty EJ; Kerger BD; Hays SM; Paustenbach DJ
Toxicol Sci; 2001 Apr; 60(2):196-213. PubMed ID: 11248132
[TBL] [Abstract][Full Text] [Related]
20. Carcinogenicity of chromium and chemoprevention: a brief update.
Wang Y; Su H; Gu Y; Song X; Zhao J
Onco Targets Ther; 2017; 10():4065-4079. PubMed ID: 28860815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
